PomegraHaemonetics Stock Jumps 15% After CSL Plasma Device Deal
Why is Haemonetics stock up today?
Haemonetics (HAE) stock rose about 15% to near $117.50 on Thursday after CSL said it will roll out the company's plasma-collection devices across all its US centers by the end of 2027.
Key numbers
| HAE share move | $117.50+15.5% vs $101.71 prior close |
|---|---|
| Premarket peak | +17%before the US open |
| CSL US sales to Haemonetics, FY2024 (per [4]) | ~$155Mabout $0.60 EPS a year |
| BTIG price target | $130from $110 |
| FY2026 revenue | $1.334B-2.0% YoY |
| FY2027 revenue growth guidance | 4-7%not updated for CSL |
What happened
Haemonetics (HAE) stock rose about 15% to near $117.50 on Thursday after CSL said it will roll out the company's plasma-collection devices across all its US centers by the end of 2027. CSL is a major collector of plasma, the part of blood used to make medicines. In August the two firms signed a deal with no minimum purchase and no set timing or number of centers. Shares were up as much as 17% before the market opened. Haemonetics will update its own forecast (guidance) in November.
Why it matters
Haemonetics now has a clearer path to selling machines and single-use supplies (disposables) to one of the biggest US plasma collectors. Disposables mean repeat sales, because each donation needs new ones. Analyst firm BTIG says CSL's US business gave Haemonetics about $155 million of sales in fiscal 2024. The deal has no minimum purchase, so its final size is still unknown.
Who this affects
- MarketbullishMedium impact
- Haemonetics shareholders gained sharply on the news; good for holders.
- CompanybullishHigh impact
- Haemonetics wins a much larger customer; good for shareholders.
- CompetitorsbearishMedium impact
- Rival plasma-device makers may lose CSL business.
- IndustryneutralMedium impact
- CSL's equipment switch could reshape US plasma device supply.
Haemonetics vs Terumo, Fresenius
| HaemoneticsHAE | $117.50 | +15.5% | — |
|---|---|---|---|
| Terumo4543.T | — | — | — |
| FreseniusFRE.DE | — | — | — |
As of 2026-10-08
How we got here
Haemonetics discloses non-exclusive CSL Plasma supply deal; no minimum purchases, scope and timing undecided.
CSL says rollout at all current US plasma centers should finish by end of 2027.
Haemonetics shares jump as much as 17% premarket and about 15% in the session.
What to watch
- Haemonetics' update on what the CSL deal means for fiscal 2027 results, due on its earnings call.2026-11
- Any change to rollout scope or timing, which Haemonetics says remain subject to change.2027-12
Educational content only. Not investment advice.
More briefsAll briefs →
Wolfspeed Stock Jumps 14% After $1.5B Defense Loan Offer
Wolfspeed (WOLF) trades near $35.89 as the Pentagon offers a 30-year loan with rights to buy up to 7.5%.
Asian Stocks Fall as Kospi Drops 2.6% on Oil and Yields
Kospi (^KS11) lost 2.62% to 6,625.93 while Japan's Nikkei fell 1.4%, as the 10-year US yield neared 5.32%.
OpenAI Valuation Jumps to $1.4T as It Seeks Pre-IPO Funding
OpenAI (private) is in talks with MGX and BlackRock for $30B+; its last round valued it at $852B.